JAMES G KELLY
Electrician in Seattle, WA
License number
Massachusetts 2445-JR
Issued Date
Aug 25, 2008
Expiration Date
Jul 31, 2013
Type
Journeyman Electrician
Address
Address
Seattle, WA 98107
Personal information
See more information about JAMES G KELLY at radaris.comName
Address
Phone
4876 NE Sheltered Bay Ln, Hansville, WA 98340
4823 Main Ave S, Renton, WA 98055
4720 119Th Pl SE, Everett, WA 98208
4703 Kingsway, Anacortes, WA 98221
5007 N Visscher St, Tacoma, WA 98407
Professional information
Enterprise Environmental Director And Counsel At Ch2M Hill
Position:
Enterprise Environmental Director and Counsel at CH2M HILL
Location:
Greater Seattle Area
Industry:
Construction
Work:
CH2M HILL
since 2000
-
Enterprise Environmental Director and Counsel
Foster Wheeler
1994 - 2000
-
Environmental Manager
Federal District Court, Washington
1993 - 1994
-
Clerk
Education:
University of Oregon School of Law
Doctor of Law (J.D.), Law University of Washington
Doctor of Law (J.D.), Law University of Washington
Onboarding Manager, Selling On Amazon
Position:
Manager, Onboarding at Amazon
Location:
Seattle, Washington
Industry:
Information Services
Work:
Amazon
since Jan 2011
-
Manager, Onboarding
Amazon.com
Mar 2010 - Jan 2011
-
Technical Engagement Manager
Speakeasy
Sep 2009 - Mar 2010
-
Advanced Business Services Manager
Speakeasy ( a Best Buy company)
Jul 2008 - Sep 2009
-
Advanced Business Support Supervisor
Speakeasy
Apr 2008 - Sep 2008
-
Advanced Business Services Technical Lead
Seanet Corp.
1999 - 2003
-
Support Representative
Education:
University of Washington 1999 - 2004
Studies, Applied and Computational Mathematics University of Washington 1999 - 2004
Studies, Applied and Computational Mathematics University of Washington 1999 - 2004
Gaffer At Espresso Parts Ltd
Position:
Gaffer at Espresso Parts Ltd
Location:
Greater Seattle Area
Industry:
Wholesale
Work:
Espresso Parts Ltd
-
Gaffer
Expression Of Biologically Active Pdgf Analogs In Eucaryotic Cells
US Patent:
4766073, Aug 23, 1988
Filed:
Aug 13, 1986
Appl. No.:
6/896485
Inventors:
Mark J. Murray - Seattle WA
James D. Kelly - Seattle WA
James D. Kelly - Seattle WA
Assignee:
ZymoGenetics Inc. - Seattle WA
International Classification:
C12N 1500, C12N 500, C12P 2100, C12P 1934
US Classification:
4351723
Abstract:
Methods for expressing a variety of biologically active PDGF analogs in eucaryotic cells are disclosed. The methods generally comprise introducing into a eucaryotic host cell a DNA construct capable of directing the expression and secretion of biologically active PDGF analogs in eucaryotic cells. The DNA construct contains a transcriptional promoter followed downstream by a suitable DNA sequence. The DNA sequence may encode a protein substantially homologous to the A-chain or the B-chain of PDGF, or a portion thereof, or an A-B heterodimer. In addition, a portion of the DNA sequence may encode at least a portion of the A-chain, while another portion encodes at least a portion of the B-chain of PDGF. Eucaryotic cells transformed with these DNA constructs are also disclosed. Methods of promoting the growth of mammalian cells, comprising incubating the cells with a biologically active PDGF analog expressed by a eucaryotic host cell transformed with such a DNA construct, are also disclosed.
Methods For Detecting Pdgf Agonist Or Antagonist Activity Using Pdgf .Alpha .
US Patent:
5618678, Apr 8, 1997
Filed:
Nov 16, 1994
Appl. No.:
8/340754
Inventors:
James D. Kelly - Seattle WA
Mark J. Murray - Seattle WA
Mark J. Murray - Seattle WA
Assignee:
ZymoGenetics, Inc. - Seattle WA
International Classification:
C12Q 100
US Classification:
435 721
Abstract:
Isolated DNA molecules that encode a novel PDGF receptor are disclosed. The receptor binds the AA, AB and BB isoforms of PDGF with high affinity. Cells transfected or transformed with the DNA molecules are also disclosed. The cells can be used within methods for detecting PDGF agonist or antagonist activity in a test compound.
Biologically Active B-Chain Homodimers
US Patent:
5428010, Jun 27, 1995
Filed:
Mar 18, 1992
Appl. No.:
7/852905
Inventors:
Mark J. Murray - Seattle WA
James D. Kelly - Seattle WA
James D. Kelly - Seattle WA
Assignee:
ZymoGenetics, Inc. - Seattle WA
International Classification:
A61K 3736
US Classification:
514 12
Abstract:
Dimeric proteins having substantially the same biological activity as PDGF are disclosed. More specifically, the protein may have two substantially identical polypeptide chains, each of the chains being substantially homologous to the B-chain of PDGF. Alternatively, the protein may have two polypeptide chains that are substantially identical to the B-chain of PDGF. In addition, proteins comprising polypeptides that are variants or derivatives of the B-chain of PDGF are also disclosed. Therapeutic compositions containing these proteins and methods for enhancing the wound-healing process in warm- blooded animals are also disclosed.
Biologically Active Mosaic Proteins
US Patent:
5498600, Mar 12, 1996
Filed:
Oct 7, 1994
Appl. No.:
8/319776
Inventors:
Mark J. Murray - Seattle WA
James D. Kelly - Seattle WA
James D. Kelly - Seattle WA
Assignee:
ZymoGenetics, Inc. - Seattle WA
International Classification:
A61K 3822, C07K 1449
US Classification:
514 12
Abstract:
Dimeric proteins having substantially the same biological activity as PDGF are disclosed. More specifically, the proteins may have two polypeptide chains, one of the chains being a mosaic of amino acid sequences substantially identical to portions of the A- or B-chains of PDGF, the second of the chains being substantially homologous to either the A-chain or the B-chain of PDGF, the proteins being chemotactic or mitogenic for fibroblasts. Alternatively, each of the two polypeptide chains may be a mosaic of amino acid sequences as described above. Therapeutic compositions containing these proteins and methods for enhancing the wound-healing process in warm-blooded animals are also disclosed.
Pdgf Analogs And Methods Of Use
US Patent:
5474982, Dec 12, 1995
Filed:
Jul 12, 1994
Appl. No.:
8/273779
Inventors:
Mark J. Murray - Seattle WA
James D. Kelly - Seattle WA
James D. Kelly - Seattle WA
Assignee:
ZymoGenetics, Inc. - Seattle WA
International Classification:
A61K 3700
US Classification:
514 12
Abstract:
Proteins having substantially the same biological activity as PDGF are provided. In one aspect, a protein homodimer having two polypeptide chains is disclosed, each of the chains being a mosaic of amino acid sequences substantially identical to portions of the A- and B-chains of PDGF, the protein being chemotactic or mitogenic for fibroblasts. Therapeutic compositions comprising such proteins in combination with a physiologically acceptable carrier or diluent are also provided. Such therapeutic compositions may be used within methods for enhancing the wound-healing process in warm-blooded animals.
Pdgf Analogs And Methods Of Use
US Patent:
5128321, Jul 7, 1992
Filed:
Aug 8, 1988
Appl. No.:
7/230190
Inventors:
Mark J. Murray - Seattle WA
James D. Kelly - Seattle WA
James D. Kelly - Seattle WA
Assignee:
ZymoGenetics, Inc. - Seattle WA
International Classification:
A61K 3737
US Classification:
514 12
Abstract:
Proteins having substantially the same biological activity as PDGF are provided. In one aspect, a protein homodimer having two polypeptide chains is disclosed, each of the chains being a mosaic of amino acid sequences substantially identical to portions of the A- and B-chains of PDGF, the protein being chemotactic or mitogenic for fibroblasts. Therapeutic compositions comprising such proteins in combination with a physiologically acceptable carrier or diluent are also provided. Such therapeutic compositions may be used within methods for enhancing the wound-healing process in warm-blooded animals.
Pdgf .Alpha. Receptor
US Patent:
5371205, Dec 6, 1994
Filed:
Sep 18, 1992
Appl. No.:
7/947358
Inventors:
James D. Kelly - Seattle WA
Mark J. Murray - Seattle WA
Mark J. Murray - Seattle WA
Assignee:
ZymoGenetics, Inc. - Seattle WA
International Classification:
C07H 2102, C12Q 168, A61K 3514, C12N 1500
US Classification:
536 235
Abstract:
Isolated DNA molecules that encode a novel PDGF receptor are disclosed. The receptor binds the AA, AB and BB isoforms of PDGF with high affinity. Cells transfected or transformed with the DNA molecules are also disclosed. The cells can be used within methods for detecting PDGF agonist or antagonist activity in a test compound.